In vitro lipolysis tests on lipid nanoparticles: Comparison between lipase/co-lipase and pancreatic extract

Drug Development and Industrial Pharmacy

Volumn 41, Issue 10, 2015, Pages 1582-1588

  Jannin, Vincent ^a   Dellera, Eleonora ^b   Chevrier, Stéphanie ^a   Chavant, Yann ^a   Voutsinas, Christophe ^a   Bonferoni, Cristina ^b   Demarne, Frédéric ^a  

^a GATTEFOSSÉ SAS   (France)

^b UNIVERSITY OF PAVIA   (Italy)

Author keywords

Digestion; Labrafac; Nanostructured lipid carriers; Pr cirol; Solid lipid nanoparticles

Indexed keywords

ACYLGLYCEROL; CARBOXYLESTERASE; COLIPASE; LONG CHAIN FATTY ACID; NANOCARRIER; NANOSTRUCTURED LIPID CARRIER; PANCREAS ENZYME; PANCREAS EXTRACT; SOLID LIPID NANOPARTICLE; TRIACYLGLYCEROL LIPASE; UNCLASSIFIED DRUG; LIPID; NANOPARTICLE;

ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; FAT INTAKE; GAS CHROMATOGRAPHY; LIPID COMPOSITION; LIPOLYSIS; NANOEMULSION; NONHUMAN; PARTICLE SIZE; PH; PHOTON CORRELATION SPECTROSCOPY; ANIMAL; BIOAVAILABILITY; CHEMISTRY; DIGESTION; DRUG RELEASE; ORAL DRUG ADMINISTRATION; PIG;

ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; CARBOXYLESTERASE; DIGESTION; DRUG LIBERATION; HYDROGEN-ION CONCENTRATION; LIPASE; LIPIDS; LIPOLYSIS; NANOPARTICLES; PANCREATIC EXTRACTS; SWINE;

EID: 84948164314     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.3109/03639045.2014.972412     Document Type: Article

References (36)

1. Muchow M, Maincent P, Müller RH. Lipid nanoparticles with a solid matrix (SLN®, NLC®, LDC®) for oral drug delivery. Drug Dev Indus Pharm 2008;34:1394-405.
2. Martins S, Sarmento B, Ferreira DC, Souto EB. Lipid-based colloidal carriers for peptide and protein delivery - liposomes versus lipid nanoparticles. Int J Nanomedicine 2007;2:595-607.
3. Mussi SV, Silva RC, Oliveira MC, et al. Anew approach to improve encapsulation and antitumor activity of doxorubicin loaded in solid lipid nanoparticles. Eur J Pharm Sci 2013;48:282-90.
4. Baek JS, Cho CW. 2-Hydroxypropyl-beta-cyclodextrin-modified SLN of paclitaxel for overcoming p-glycoprotein function in multidrug-resistant breast cancer cells. J Pharm Pharmacol 2013; 65:72-8.
5. Sandri G, Bonferoni MC, Gokce EH, et al. Chitosan-associated SLN: in vitro and ex vivo characterization of cyclosporine A loaded ophthalmic systems. J Microencapsul 2010;27:735-46.
6. Fonte P, Andrade F, Araujo F, et al. Chitosan-coated solid lipid nanoparticles for insulin delivery. Methods Enzymol 2012;508: 295-314.
7. Muller RH, Radtke M, Wissing SA. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Adv Drug Deliv Rev 2002;54:S131-55.
8. Kathe N, Henriksen B, Chauhan H. Physicochemical techniques for solid lipid nanoparticles: principles and limitations. Drug Dev Indus Pharm 2014. [Epub ahead of print].10.3109/03639045.2014.909840.
9. Bakala N'Goma JC, Amara S, Dridi K, et al. Understanding the lipid-digestion processes in the GI tract before designing lipid-based drug-delivery systems. Ther Deliv 2012;3:105-24.
10. Carriere F, Barrowman JA, Verger R, Laugier R. Secretion and contribution to lipolysis of gastric and pancreatic lipases during a test meal in humans. Gastroenterology 1993;105:876-88.
11. Lengsfeld H, Beaumier-Gallon G, Chahinian H, et al. Physiology of gastrointestinal lipolysis and therapeutical uses of lipases and digestive lipase inhibitors. In: Müller G, Petry S, eds. Lipases and phospholipases in drug development. Weinheim: Wiley-VCH; 2004:195-229.
12. Bernback S, Blackberg L, Hernell O. Fatty acids generated by gastric lipase promote human milk triacylglycerol digestion by pancreatic colipase-dependent lipase. Biochim Biophys Acta 1989; 1001:286-93.
13. Gargouri Y, Pieroni G, Riviere C, et al. Importance of human gastric lipase for intestinal lipolysis: an in vitro study. Biochim Biophys Acta 1986;879:419-23.
14. De Caro J, Carriere F, Barboni P, et al. Pancreatic lipase-related protein 1 (PLRP1) is present in the pancreatic juice of several species. Biochim Biophys Acta 1998;1387:331-41.
15. De Caro J, Sias B, Grandval P, et al. Characterization of pancreatic lipase-related protein 2 isolated from human pancreatic juice. Biochim Biophys Acta 2004;1701:89-99.
16. Giller T, Buchwald P, Blum-Kaelin D, Hunziker W. Two novel human pancreatic lipase related proteins, hPLRP1 and hPLRP2. Differences in colipase dependence and in lipase activity. J Biol Chem 1992;267:16509-16.
17. Eydoux C, De Caro J, Ferrato F, et al. Further biochemical characterization of human pancreatic lipase-related protein 2 expressed in yeast cells. J Lipid Res 2007;48:1539-49.
18. Lombardo D, Fauvel J, Guy O. Studies on the substrate specificity of a carboxyl ester hydrolase from human pancreatic juice. I. Action on carboxyl esters, glycerides and phospholipids. Biochim Biophys Acta 1980;611:136-46.
19. Fernandez S, Najjar A, Robert S, et al. Specific assay of carboxyl ester hydrolase using PEG esters as substrate. Anal Methods 2010;2: 1013-9.
20. Blackberg L, Hernell O. Bile salt-stimulated lipase in human milk. Evidence that bile salt induces lipid binding and activation via binding to different sites. FEBS Lett 1993;323:207-10.
21. Williams HD, Anby MU, Sassene P, et al. Toward the establishment of standardized in vitro tests for lipid-based formulations. 2. The effect of bile salt concentration and drug loading on the performance of type I, II, IIIA, IIIB, and IV formulations during in vitro digestion. Mol Pharm 2012;9:3286-300.
22. Williams HD, Sassene P, Kleberg K, et al. Toward the establishment of standardized in vitro tests for lipid-based formulations, part 1: method parameterization and comparison of in vitro digestion profiles across a range of representative formulations. J Pharm Sci 2012;101:3360-80.
23. Olbrich C, Kayser O, Muller RH. Lipase degradation of dynasan 114 and 116 solid lipid nanoparticles (SLN) - effect of surfactants, storage time and crystallinity. Int J Pharmaceut 2002; 237:119-28.
24. Hron WT, Menahan LA. A sensitive method for the determination of free fatty acids in plasma. J Lipid Res 1981;22:377-81.
25. Troncoso E, Aguilera JM, McClements DJ. Influence of particle size on the in vitro digestibility of protein-coated lipid nanoparticles. J Colloid Inteface Sci 2012;382:110-16.
26. Fernandez S, Chevrier S, Ritter N, et al. In Vitro gastrointestinal lipolysis of four formulations of piroxicam and cinnarizine with the self emulsifying excipients Labrasol® and Gelucire® 44/14. Pharm Res 2009;26:1901-10.
27. Gokce EH, Korkmaz E, Dellera E, et al. Resveratrol-loaded solid lipid nanoparticles versus nanostructured lipid carriers: evaluation of antioxidant potential for dermal applications. Int J Nanomedicine 2012;7:1841-50.
28. Fernandez S, Jannin V, Rodier JD, et al. Comparative study on digestive lipase activities on the self emulsifying excipient Labrasol®, medium chain glycerides and PEG esters. Biochim Biophys Acta 2007;1771:633-40.
29. Fernandez S, Rodier JD, Ritter N, et al. Lipolysis of the semi-solid self-emulsifying excipient Gelucire® 44/14 by digestive lipases. Biochim Biophys Acta 2008;1781:367-75.
30. Fernandez S, Jannin V, Chevrier S, et al. In vitro digestion of the self-emulsifying lipid excipient labrasol by gastrointestinal lipases and influence of its colloidal structure on lipolysis rate. Pharm Res 2013;30:3077-87.
31. Noack A, Oidtmann J, Kutza J, Mäder K. In vitro digestion of curcuminoid-loaded lipid nanoparticles. J Nanopart Res 2012;14: 1113-32.
32. Bonnaire L, Sandra S, Helgason T, et al. Influence of lipid physical state on the in vitro digestibility of emulsified lipids. J Agric Food Chem 2008;56:3791-7.
33. Jeon HS, Seo JE, Kim MS, et al. A retinyl palmitate-loaded solid lipid nanoparticle system: effect of surface modification with dicetyl phosphate on skin permeation in vitro and anti-wrinkle effect in vivo. Int J Pharm 2013;452:311-20.
34. Khalil RM, Abd-Elbary A, Kassem MA, et al. Nanostructured lipid carriers (NLCs) versus solid lipid nanoparticles (SLNs) for topical delivery of meloxicam. Pharm Dev Technol 2014;19: 304-14.
35. Feeney OM, Williams HD, Pouton CW, Porter CJ. 'Stealth' lipidbased formulations: poly(ethylene glycol)-mediated digestion inhibition improves oral bioavailability of a model poorly water soluble drug. J Control Release 2014;192C:219-27.
36. Bakala-N'Goma JC, Williams HD, Sassene P, et al. Toward the establishment of standardized in vitro tests for lipid-based formulations. 5. Lipolysis of representative formulations by gastric lipase. Eur J Pharm Biopharm. 2014. [Epub ahead of print].